ranolazine has been researched along with Brugada ECG Pattern in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelsayed, M; Ruben, PC; Ruprai, M | 1 |
| Belardinelli, L; Kanas, AF; Morrow, DA; Nearing, BD; Nieminen, T; Pagotto, VP; Pegler, JR; Scirica, BM; Sobrado, MF; Tavares, C; Umez-Eronini, AA; Verrier, RL | 1 |
| Chao, TF; Chen, SA; Chen, YC; Chen, YJ; Chung, FP; Huang, JH; Kao, YH; Lu, YY; Tsai, CF | 1 |
| Belardinelli, L; Bhimani, AA; Khrestian, CM; Lee, S; Sadrpour, SA; Waldo, AL; Yasuda, T; Zeng, D | 1 |
1 trial(s) available for ranolazine and Brugada ECG Pattern
| Article | Year |
|---|---|
Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Death, Sudden, Cardiac; Electrocardiography; Enzyme Inhibitors; Female; Heart Conduction System; Humans; Male; Middle Aged; Piperazines; Placebos; Predictive Value of Tests; Ranolazine; Risk Factors; Tachycardia, Ventricular; Treatment Outcome | 2014 |
3 other study(ies) available for ranolazine and Brugada ECG Pattern
| Article | Year |
|---|---|
The efficacy of Ranolazine on E1784K is altered by temperature and calcium.
Topics: Action Potentials; Brugada Syndrome; Calcium; Cardiac Conduction System Disease; HEK293 Cells; Humans; Long QT Syndrome; Mutation; NAV1.5 Voltage-Gated Sodium Channel; Ranolazine; Sodium; Temperature | 2018 |
Distinctive electrophysiological characteristics of right ventricular out-flow tract cardiomyocytes.
Topics: Acetanilides; Action Potentials; Animals; Arrhythmias, Cardiac; Benzylamines; Brugada Syndrome; Calcium; Cardiac Conduction System Disease; Electrophysiological Phenomena; Enzyme Inhibitors; Heart Conduction System; Heart Ventricles; Myocytes, Cardiac; Patch-Clamp Techniques; Piperazines; Protein Kinase Inhibitors; Rabbits; Ranolazine; Sodium-Calcium Exchanger; Sulfonamides | 2014 |
Ranolazine terminates atrial flutter and fibrillation in a canine model.
Topics: Acetanilides; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Brugada Syndrome; Cardiac Conduction System Disease; Disease Models, Animal; Dogs; Electrocardiography; Enzyme Inhibitors; Heart Conduction System; Heart Rate; Injections, Intravenous; Piperazines; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2014 |